Navigation Links
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Date:8/5/2008

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are giving three presentations at two conferences this week.

Gordon Research Conference on Medicinal Chemistry, August 3-8

Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon Research Conference on Medicinal Chemistry this week at Colby Sawyer College, New London, NH. Dr. Bhattacharjee introduced Rib-X's enhanced macrolide program in a poster session titled, "Structure-Based Drug Design Targeting Infectious Disease: Overcoming Resistance and Extending the Antimicrobial Spectrum of Macrolide Antibiotics." In his presentation on August 3 and 4, Dr. Bhattacharjee highlighted how the combination of structural insights from X-ray crystallographic studies of known and new antibiotics bound to the bacterial 50S ribosomal subunit with data-driven computational chemistry tools allows for a fresh look at macrolide antibiotics.

Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.

Drug Discovery & Development of Innovative Therapeutics World Conference, August 4-7

Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X Pharmaceuticals, Inc., is presenting Rib-X's RX-04 program at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Conference Technology Conference today at 11:00 A
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
5. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Inc. (Nasdaq: ANTH ), today announced financial results ... Financial Results: Total operating ... $18.7 million, as compared to $6.5 million for the same ... quarter of 2011 were driven by expenses related to site ...
... STAAR Surgical Company (NASDAQ: STAA ), ... ophthalmic products, today reported financial results for the first ... increased 8% to $14.8 million over the first quarter ... (IOL and ICL) sales.  The Company achieved its first ...
Cached Medicine Technology:Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 2STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 3STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 4STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 6STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 7STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 8STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 9STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 10STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 11
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, Manganese, ... Chelated), Application Mode (Soil, Foliar, Fertigation), Crop Type ... 2018” defines and segments the global agriculture micronutrients ... global value and volume for agriculture micronutrients. It ... the global agriculture micronutrients market with an analysis ...
(Date:7/13/2014)... 2014 According to a new ... Market by Component (processor, GPU, DSP, connectivity), Technology ... and Geography - Forecast and Analysis to 2014-2020", ... & Computing Market is expected to reach $61.70 ... 20.75% from 2014 to 2020. , Browse 71 ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, 2014 ... people with diabetes is being developed to measure sugar levels ... Scientists at Brown University in Providence, R.I., created the ... light, metal and a special enzyme that changes color when ... to prick their fingers to draw blood to check their ...
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & ... second bellwether trial, which is expected to get underway ... issued in the U.S. District Court, Southern District of ... will be held on August 7, 2014 at 3:00 ...
(Date:7/13/2014)... MyDressCity.com, one of the most popular suppliers of wedding ... new range of elegant Quinceanera dresses . What’s ... prices. Worldwide clients can enjoy this special offer before ... shop, there are plenty of beautiful dresses for sale, ... MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, wedding ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2
... repair damage with natural tissue , THURSDAY, Feb. 4 ... cartilage growth in joints has been developed by U.S. ... joint and stimulates bone marrow stem cells to produce ... No current therapy can do this, according to the ...
... typical 30-hour shifts need to be cut to 16 to ... In November 2000, Helen Haskell took her 15-year-old son to ... Four days later, he was dead. The cause: failure to ... to recognize and act upon declines in patients." , He ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , TORRANCE, ... the largest privately held insurance brokerage and consulting firm in ... providers of integrated disease management and wellness programs.  Nurtur and ... program providers, adding an important dimension to the company,s extensive ...
... , , NEW YORK , ... Parkinson,s Research today announced more than $2.8 million ... of biomarkers of PD. The development of biomarkers is of ... therapeutic development, allowing scientists and clinicians to more accurately identify ...
... , Feb 4 Smart Balance, Inc. (Nasdaq: SMBL ... February 25, 2010 , at 9:30 a.m. ET to ... 8:30 a.m. ET the same day.  The webcast will be in ... by dialing 1-800-895-0198 from the United States or 1-785-424-1053 from ...
Cached Medicine News:Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Campaign Calls for Limits on Doctors' Hours 2Health News:Campaign Calls for Limits on Doctors' Hours 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 2Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 3Health News:Keenan Selects Nurtur and Healthyroads for Integrated Disease Management and Personal Wellness Programs 4Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2
... The MEL 80 is a top quality ... the correction of vision defects even safer, ... of this ultramodern work platform are oriented ... and the rapid recovery of vision. Key ...
Code-Ready defibrillator a defibrillator designed to provide clinicians with comprehensive support for resuscitation....
... be mounted at the patient's bedside, on ... The design retains many of the proven ... the pump drive motor circuits, flow estimator, ... system. Retaining these subsystems maintains compatibility ...
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: